Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

MAP2K2 mutation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

MAP2K2 mutation + TMB-H (1)

MAP2K2 mutation + TMB-H (1)

›

MAP2K2 mutation	Melanoma	MAP2K2 mutation	Melanoma	CTLA4 inhibitor Sensitive: C3 – Early Trials CTLA4 inhibitor Sensitive : C3	CTLA4 inhibitor Sensitive: C3 – Early Trials CTLA4 inhibitor Sensitive : C3
MAP2K2 mutation	Pancreatic Ductal Adenocarcinoma	MAP2K2 mutation	Pancreatic Ductal Adenocarcinoma	avelumab + binimetinib Sensitive: C3 – Early Trials avelumab + binimetinib Sensitive : C3	avelumab + binimetinib Sensitive: C3 – Early Trials avelumab + binimetinib Sensitive : C3
MAP2K2 mutation	Melanoma	MAP2K2 mutation	Melanoma	dabrafenib Resistant: D – Preclinical dabrafenib Resistant : D	dabrafenib Resistant: D – Preclinical dabrafenib Resistant : D
MAP2K2 mutation	Melanoma	MAP2K2 mutation	Melanoma	trametinib Resistant: D – Preclinical trametinib Resistant : D	trametinib Resistant: D – Preclinical trametinib Resistant : D